Robert W. Baird Forecasts Strong Price Appreciation for Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics (NASDAQ:BBNX) had its target price raised by equities research analysts at Robert W. Baird from $14.00 to $16.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s price target suggests a potential downside of 4.36% from the company’s previous close.

Several other brokerages also recently weighed in on BBNX. Bank of America lowered their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Leerink Partners lifted their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Truist Financial upped their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, The Goldman Sachs Group lifted their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

Beta Bionics Trading Up 1.0%

Shares of BBNX stock opened at $16.73 on Tuesday. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The business’s fifty day simple moving average is $17.30 and its 200-day simple moving average is $13.82. The company has a market cap of $752.68 million, a PE ratio of -10.14 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million during the quarter. On average, equities analysts forecast that Beta Bionics will post -2.1 earnings per share for the current year.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, insider Steven Russell sold 4,221 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the transaction, the insider directly owned 169,628 shares of the company’s stock, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20. Following the completion of the transaction, the insider owned 87,157 shares of the company’s stock, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 70,132 shares of company stock valued at $1,284,623 in the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

Several institutional investors have recently bought and sold shares of BBNX. Perceptive Advisors LLC lifted its stake in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock valued at $8,446,000 after buying an additional 240,000 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Beta Bionics in the second quarter worth approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Beta Bionics in the fourth quarter worth approximately $40,437,000. Bruce & Co. Inc. purchased a new stake in shares of Beta Bionics during the first quarter worth approximately $5,518,000. Finally, Y Intercept Hong Kong Ltd lifted its holdings in Beta Bionics by 4,236.8% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock valued at $4,868,000 after purchasing an additional 474,651 shares in the last quarter.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Mint™, Beta Bionics’ reusable-and-disposable patch insulin pump. The device does not require recharging, supports leading continuous glucose monitors, and allows smartphone control, potentially expanding the company’s addressable market ahead of a planned 2027 launch. Beta Bionics Announces FDA Clearance of Mint
• Positive Sentiment: Beta Bionics and Senseonics announced plans to integrate Senseonics’ Eversense 365 one-year continuous glucose monitor with the iLet Bionic Pancreas, with a commercial launch targeted for the fourth quarter of 2026. The partnership could improve the iLet ecosystem and broaden its appeal to diabetes patients. Senseonics Announces Partnership with Beta Bionics
• Neutral Sentiment: The company also unveiled 3D Intelligence™, a next-generation insulin-dosing algorithm. While the technology may support future product development, its near-term financial impact remains uncertain.
• Negative Sentiment: Beta Bionics lowered its 2026 revenue guidance, raising concerns about near-term demand, execution, or commercialization momentum. The guidance reduction offsets some of the optimism from the Mint clearance. Beta Bionics Lowers 2026 Revenue Guidance
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action covering investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. The complaints allege that Beta Bionics misled investors about the iLet’s safety, efficacy, commercial prospects, and handling of customer complaints. The allegations have not been proven, but the litigation creates legal, reputational, and potential financial risks; the lead-plaintiff deadline is November 3, 2026. BBNX Court Alert

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.